Published On: Wed, Oct 19th, 2016

Analyst Review: Horizon Pharma, Inc. (NASDAQ:HZNP)


A number of investment brokers have recently updated their price targets on shares of Horizon Pharma, Inc. (NASDAQ:HZNP).

Most recent broker ratings

09/30/2016 – Horizon Pharma, Inc. was upgraded to “strong buy” by analysts at Vetr Inc..

09/27/2016 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 27 price target on the stock.

09/16/2016 – Horizon Pharma, Inc. was downgraded to “market perform” by analysts at Cowen. They now have a USD 42 price target on the stock.

09/13/2016 – Horizon Pharma, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 30 price target on the stock.

09/13/2016 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at Mizuho. They now have a USD 33 price target on the stock.

08/23/2016 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 30 price target on the stock.

08/08/2016 – Horizon Pharma, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 33 price target on the stock.

07/14/2016 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 30 price target on the stock.

07/11/2016 – Horizon Pharma, Inc. was upgraded to “equal-weight” by analysts at Morgan Stanley. They now have a USD 24 price target on the stock.

07/06/2016 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 45 price target on the stock.

05/23/2016 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 24 price target on the stock.

03/02/2016 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 31 price target on the stock.

01/06/2016 – Horizon Pharma, Inc. had its “neutral” rating reiterated by analysts at Citigroup.

10/22/2015 – Horizon Pharma, Inc. had its “buy” rating reiterated by analysts at JMP Securities.

07/07/2015 – Horizon Pharma, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 37 price target on the stock.

The share price of Horizon Pharma, Inc. (NASDAQ:HZNP) was up +2.73% during the last day of trading, with a day high of 18.22. 1794647 shares were traded during the last session.

The stock’s 50 day moving average is 18.60 and its 200 day moving average is 17.91. The stock’s market capitalization is 2.90B. Horizon Pharma, Inc. has a 52-week low of 12.86 and a 52-week high of 23.70.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, known as LODOTRA.